Core Viewpoint - Guangdong Mingzhu (600382) expects a significant increase in net profit for 2025, projecting a growth of 2908.49% to 3577.04% year-on-year, driven by operational improvements and increased sales in iron ore and construction materials [4]. Financial Performance - The company forecasts a net profit attributable to shareholders of 166 million to 203 million yuan for 2025, and a non-recurring net profit of 175 million to 213 million yuan, reflecting a year-on-year increase of 422.59% to 538.72% [4]. - As of January 30, the company's price-to-earnings (P/E) ratio is approximately 32.64 to 39.9 times, with a price-to-book (P/B) ratio of about 2.44 times and a price-to-sales (P/S) ratio of around 7.92 times [4]. Operational Factors - The increase in profit is attributed to the full subsidiary Guangdong Mingzhu Group Mining Co., which has seen a 160.83% increase in iron concentrate sales due to new mining operations and technological upgrades in production lines [14]. - The company expects a net profit from the mining segment to be between 349.45 million to 427.11 million yuan, representing a year-on-year increase of 208.00% to 276.45% [14]. Non-Operating Factors - The company anticipates a decrease in expenses related to investor claims for securities fraud, compared to the previous year [16]. - Gains from the fair value changes of stock investments are expected to increase by 1.09 million yuan year-on-year [17]. Impairment and Valuation Adjustments - The company plans to increase impairment provisions for real estate projects due to ongoing legal issues, with an expected credit impairment of approximately 93.64 million yuan, a year-on-year increase of about 485.86% [18].

Core Viewpoint - Zhengfan Technology (688596) expects a decline in revenue and net profit for the year 2025, indicating challenges in the market and operational environment [4]. Financial Performance Summary - The projected revenue for 2025 is between 4.8 billion to 5.1 billion yuan, representing a year-on-year decrease of 7% to 12% [4]. - The expected net profit attributable to shareholders is between 110 million to 150 million yuan, reflecting a significant decline of 72% to 79% year-on-year [4]. - The forecasted net profit excluding non-recurring items is estimated to be between 65 million to 95 million yuan, indicating a decrease of 81% to 87% year-on-year [4]. Valuation Metrics - As of January 30, the price-to-earnings ratio (TTM) is approximately between 65.14 and 88.83 times, while the price-to-book ratio (LF) is about 2.71 times, and the price-to-sales ratio (TTM) is around 1.97 times [4]. Factors Influencing Performance - The decline in performance is attributed to several factors: 1. A slowdown in capital expenditure from downstream industries, increased market competition, and delays in project deliveries, leading to reduced revenue and gross profit [13]. 2. Increased depreciation due to the concentrated use of newly built production capacity [13]. 3. Rising financial costs from investments, bank loans, and convertible bond issuances [13].

-○- 公司 -○- 行业均值 中证智能财讯盈新发展（000620）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润亏损9.5亿元至12亿元，上年同期亏损5.33亿元；扣非净利润 亏损9.93亿元至12.54亿元，上年同期亏损7.06亿元；基本每股收益-0.16元/股至-0.2元/股。以最新收盘价计算，市净率（LF）约4.41倍，市销率（TTM）约 10.13倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况（倍） 100 @ 20 7.53 0 142 4 8 දි 0:77 -50 -100 -138.23 -150 2022-06-30 2027-12-37 2020-12-37 ! 2021-06-30 2022-12-37 : 2023-12-37 J24-06-30 23-06-30 ; 2n- 资料显示，公司为一家集文旅景区开发运营、酒店管理、旅行社、房地产开发、建筑施工、物业服务、规划设计等多产业布局、具备多业态综合开发能力的 上市公司。 100 ହ 90 80 70 60 50 40 30 20 10 9:2 0 - 2020-12- ...

中证智能财讯硕世生物（688399）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润亏损2940万元至4400万元，上年同期亏损200.17万元；扣非 净利润亏损8190万元至1.23亿元，上年同期亏损7183.71万元。以最新收盘价计算，市净率（LF）约2.03倍，市销率（TTM）约17.79倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况（倍） 150 116.17 50 1883 0 2 82 - 50 - 100 -15 -200 -250 2022-06-30 ' 2021-12-37 2021-06-30 ' 2022-12-37 0-12-37 3-06-30 13-12-3- 2n- -○- 公司 -○- 行业均值 100 94,52 ହ 90 80 70 67o87 60 57:88 50 4476 40 30 26:05 20 10 d to #37 0 2027-12-37 | 2020-12-37 1 2022-12-37 3-06-30 ' 3-12-37 . 7-06-30 , 2022-06-30 ' 2n- ） 制图数 ...

以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况 (倍) 中证智能财讯跃岭股份（002725）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润1200万元至1800万元，同比下降61.86%-74.57%；扣非净利润 预计270万元-405万元，同比下降16.03%-44.02%；基本每股收益0.0469元/股-0.0703元/股。以1月30日收盘价计算，跃岭股份目前市盈率（TTM）约为211.63 倍-317.44倍，市净率（LF）约3.7倍，市销率（TTM）约5.57倍。 600 @00 436.1 200 180.28 94~11 0 -60.62 58.4 -144-39 -177.65 -200 -319.94 -400 2021-06-30 2021-12-37 202-06-30 2020-12-37 2022-12-37 3-06-30 3-12-37 2n- -○- 公司 -○- 行业均值 100 97658 ହ 90 81~43 80 70 6843 60 50 40 30 20 10 0 2020-12-37 1 2027-12-37 ...

中证智能财讯朗科智能（300543）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润1100万元至1650万元，同比下降68.09%-78.73%；扣非净利润 预计700万元-1050万元，同比下降77.05%-84.7%。以1月30日收盘价计算，朗科智能目前市盈率（TTM）约为210倍-315.01倍，市净率（LF）约2.36倍，市销 率（TTM）约2.11倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况 (倍) 300 @50 200 150 100 50 47 64 45 02 24x72 23:02 21o77 0 2020-12-37 1 2027-12-37 1 ·7-06-30 ' 2022-12-37 5-30 2n- -○- 公司 -○- 行业均值 100 ହ 90 80 70 65x35 63a 60 58.16 50 46.97 40 38.41 30 20 -11-58 10 8.64 6.97 0 2027-12-37 1 2020-12-37 2-12-37 · 5-12-37 . 2-06-30 -06-30 2n- ← ...

Core Viewpoint - The company is experiencing a decline in net profit and gross margin due to macroeconomic changes and intensified industry competition, but it is focusing on expanding its domestic and international business to drive high-quality growth in core operations. Company Performance - The company's main business includes early-stage drug evaluation, non-clinical research, and clinical testing and translational research [9] - The net profit attributable to shareholders and the net profit after deducting non-recurring gains and losses decreased compared to the same period last year [9] - In 2025, the company signed new orders worth RMB 1.135 billion, a year-on-year increase of 38.62%, with overseas orders amounting to RMB 74.772 million [9] - By the end of 2025, the company's backlog of orders reached RMB 1.248 billion, an increase of 28.23% from the end of 2024 [9] Industry Context - The CRO industry is facing downward pressure on sales order prices due to changes in the macro environment and increased competition [9] - The overall sales performance in the industry is being impacted, leading to a decline in gross margins for companies within the sector [9]

Group 1 - The company expects a net loss attributable to shareholders of 250 million to 500 million yuan for the year 2025, compared to a loss of 470 million yuan in the same period last year [2] - The company's non-recurring net profit is projected to be a loss of 280 million to 560 million yuan, with the previous year's loss being 462 million yuan [2] - The basic earnings per share are estimated to be between -0.1451 yuan and -0.2901 yuan [2] Group 2 - The company's main business includes landscape engineering construction, landscape design, architectural design, seedling planting production, and landscape maintenance services, providing integrated services to clients [11] - The company's revenue and gross profit have declined due to intensified market competition and extended project settlement cycles [11] - The company plans to recognize impairment losses on accounts receivable, contract assets, and long-term receivables based on cautious principles, with specific amounts to be determined after audit [11]

Company Performance - The company, Tenglong Co., Ltd. (603158), expects to achieve operating revenue of 3.965 billion to 4.382 billion yuan in 2025, representing a year-on-year growth of 3.97% to 14.92% [4] - The net profit attributable to shareholders is projected to be between 46 million and 69 million yuan, indicating a significant decline of 72.38% to 81.59% year-on-year [4] - The expected net profit after deducting non-recurring gains and losses is estimated to be between 28.8 million and 51.8 million yuan, reflecting a decrease of 72.21% to 84.55% year-on-year [4] Valuation Metrics - As of January 30, the company's price-to-earnings (P/E) ratio (TTM) is approximately between 73.69 and 110.53 times, while the price-to-book (P/B) ratio (LF) is about 2.19 times, and the price-to-sales (P/S) ratio (TTM) is around 1.22 times [4] Business Overview - The company specializes in the research, development, production, and sales of automotive thermal management components and is recognized as a leading domestic automotive parts manufacturer [13] - The performance fluctuation is attributed to steady growth in the main business, increased industry competition, and the ramp-up period of new projects in Poland and Anhui, leading to higher fixed asset depreciation and a slight decline in gross margin [13] - The company has implemented various measures to improve profitability, including cost reduction in the supply chain and enhancing operational efficiency, which are gradually showing results [13]

以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 资料显示，公司主营POCT试剂及仪器。 中证智能财讯安旭生物（688075）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润7100万元至8500万元，同比下降55.8%-63.08%；扣非净利润 预计1300万元-1560万元，同比下降58.84%-65.7%。以1月30日收盘价计算，安旭生物目前市盈率（TTM）约为60.16倍-72.03倍，市净率（LF）约0.99倍，市 销率（TTM）约11.05倍。 此外，美国政府加征关税使得部分区域市场订单减少，公司承担部分关税导致营业成本上升，加上汇率波动引起汇兑损失、利息收入降低及资产折旧摊销等 多方面原因导致利润同比下滑。 指标注解： 据公告，公司业绩变动原因为， 报告期内，公司主营业务保持稳健发展，为巩固在产业领域内的长期竞争优势，公司保持原有几大技术平台的先进性之 外，持续加大对新技术平台的战略性投入，同时国内外市场及注册证书等拓展，海外分子公司的布局致使费用增加。 市盈率=总市值/净利润。当公司亏损时市盈率为负，此时用市盈率估值没有实际意义，往往用市净率或市销率做参考。 市 ...